Brief: Curis Says FDA Allows Patient Enrollment To Resume In Leukemia Study

Curis

30/08/2022 13:24

Aug 30 (Reuters) - Curis Inc  CRIS.O :
    * FDA ALLOWS PATIENT ENROLLMENT TO RESUME IN MONOTHERAPY
DOSE
ESCALATION OF EMAVUSERTIB IN TAKEAIM LEUKEMIA STUDY
    * CURIS INC - PRELIMINARY CLINICAL DATA UPDATE EXPECTED IN
2023
    * CURIS INC - CURIS WORKING WITH CLINICAL SITES TO RESUME
ENROLLMENT

Source text for Eikon:  ID:nPn5LRlfa 
Further company coverage:  CRIS.O 

 ((Reuters.Briefs@thomsonreuters.com;))